Journey Medical Corporation
DERMAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Oct 26, 2026 |
| B. Riley Securities | maintain | Buy | Aug 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 26, 2026 |
| Lake Street | maintain | Buy | Aug 13, 2025 |
| B. Riley Securities | maintain | Buy | Jul 30, 2025 |
| B. Riley Securities | maintain | Buy | Sep 7, 2023 |
| B. Riley Securities | maintain | Buy | Jul 12, 2023 |
| B. Riley Securities | maintain | Buy | May 23, 2023 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.03| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.01 | $-0.02 | $18.5M | $18.4M |
| May 13, 2026 | $-0.08 | $-0.07 | $16.0M | $15.5M |
| Mar 25, 2026 | $-0.04 | $-0.06 | $16.1M | $18.9M |
| Nov 12, 2025 | $-0.09 | $-0.08 | $17.6M | $18.9M |
| Aug 12, 2025 | $-0.16 | $-0.07 | $15.0M | $18.9M |
| May 14, 2025 | $-0.18 | $-0.24 | $13.1M | $14.9M |
| Mar 26, 2025 | $0.08 | $-0.22 | $13.6M | $12.1M |
| Nov 12, 2024 | $-0.12 | $-0.17 | $14.6M | $14.2M |
News
Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET
Journey Medical (NASDAQ: DERM - Get Free Report) and Vireo Growth (OTCMKTS:VREOD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Risk and Volatility Journey Medical has a
Journey Medical (DERM) is rated Buy, driven by Emrosi's rapid prescription growth and expanding payer coverage. DERM leverages existing infrastructure for Emrosi, achieving high gross margins and operating leverage, pushing toward sustainable profitability. Conservative growth assumptions and a 4x EV/Sales multiple yield a $15 target price, implying 109% upside over three years.
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
Journey Medical demonstrates strong Emrosi prescription growth, rebounding from Q1 lows with Q2 revenues up 23% to $18.5M and positive EBITDA. DERM's Emrosi franchise is gaining traction, with prescribers rising over 40% quarter-over-quarter and formulary coverage improving from 34% to 38%. Cost discipline is evident as SG&A declined and operating expenses rose less than 1%, while Emrosi's ASP and market penetration are expected to improve further.
Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript
The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.